Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b, Open Label, Dose Escalation Study of IOA-289, an Orally Bioavailable, Selective Autotaxin (ENPP2) Inhibitor Alone and in Combination With Gemcitabine/Nab-paclitaxel in Patients With Metastatic Pancreatic Cancer

Next Previous
X
Search
Trial Profile

A Phase 1b, Open Label, Dose Escalation Study of IOA-289, an Orally Bioavailable, Selective Autotaxin (ENPP2) Inhibitor Alone and in Combination With Gemcitabine/Nab-paclitaxel in Patients With Metastatic Pancreatic Cancer

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Jun 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gemcitabine (Primary) ; IOA 289 (Primary) ; Paclitaxel (Primary)
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Adverse reactions
  • Acronyms AION-01
  • Sponsors iOnctura

    • Most Recent Events

    • 04 Jun 2024 Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 04 Mar 2024 Planned End Date changed from 17 Apr 2024 to 1 Feb 2025.
    • 04 Mar 2024 Planned primary completion date changed from 17 Oct 2023 to 1 Dec 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top